Background: Positron-emission tomography/computed tomography (PET/CT) and positron-emission tomography/magnetic resonance imaging (PET/MRI) are hybrid medical imaging techniques that are becoming increasingly important in the diagnostic workup of cancer. Correct definition and interpretation of results are key challenges for both radiologists/specialists in nuclear medicine as well as for the treating clinician. Strong interdisciplinary communication is prerequisite to solve the upcoming complexity of retrieved information generated by hybrid imaging.
Objectives: Different indications for hybrid medical imaging and review of current theranostic principles from the perspective of clinicians/clinical oncologists.
Materials and methods: The GBA guidelines and recommendations retrieved from the corresponding German S3 guidelines for the use of PET imaging are summarized, followed by a review of innovative clinical trials that promote PET-based therapeutic strategies and radioligand therapies.
Results: Next generation PET/CT and PET/MRI imaging are being increasingly used for diagnostic purposes and follow-up staging in malignant tumors. Radioligand therapy may have the potential to be a further cornerstone in personalized antitumor therapy.
Conclusions: Careful implementation of hybrid medical imaging can clearly improve the quality of the diagnosis in cancer patients and even increase the quality of care for cancer patients. Close interdisciplinary collaboration is essential to optimize therapeutic strategies for each patient.
Keywords: Hybrid imaging; Metabolic response; Positron-emission tomography; Prostate-specific membrane antigen; Theranostic.